The most promising emerging ICB target is LAG-3. point to melanoma as an immune responsive tumor. First, 5% of melanoma patients present with metastatic disease that genotypically resembles cutaneous melanoma, but without an identifiable primary melanoma, suggesting that the primary tumor may have spontaneously regressed1. Second, melanoma is often associated with vitiligo the manifestation of an autoimmune reaction RC-3095 against melanocytes, indicating cross-reactive immune responses targeting melanoma and normal melanocytes. Vitiligo was shown to be a favorable prognostic indicator in patients2, suggesting that anti-melanocytic immune responses help control melanoma growth. Third, melanoma can be infiltrated by reactive lymphocytes3, with dense infiltration of peri-tumoral lymphocytes being associated with better prognosis, and melanoma classification based on tumor-infiltrating lymphocyte (TIL) distribution (brisk, non-brisk and absent) is still used today47. However, melanoma disseminates and metastasizes very easily, indicating that active immune suppression or dysfunction must offset its immunogenicity. Reliance on immune evasion mechanisms for disease progression may underscore the specific vulnerability of melanoma to immunotherapy, thus explaining its unique responsiveness to these treatments. The concept of immune checkpoint blockade (ICB) for the treatment of cancer was pioneered by Jim Allison and colleagues showing that antibodies blocking the T cell co-inhibitory receptor CTLA-4 can regress tumors in mice8. Human CTLA-4 blocking antibodies were then developed and tested in patients, with ipilimumab becoming the first therapy to extend survival in metastatic melanoma9,10, which led to its approval in MGC4268 this disease in 2011. PD-1 was recognized as another key T cell immune checkpoint11. PD-1 or PD-L1 blocking antibodies were found to enhance tumor control in mice12,13and CD8+T cell functionality in a chronic viral infection model14. Promising results in early clinical trials with PD-1 blocking antibodies in refractory solid tumors were confirmed in phase-3 studies in melanoma, where the PD-1 inhibitors pembrolizumab and nivolumab were found to extend survival compared to ipilimumab or chemotherapy1519. These agents were then approved for the treatment of metastatic melanoma in 2014. Overall, the clinical success with ICB in melanoma has confirmed the therapeutic impact of re-invigorating RC-3095 the immune system to effectively target this disease. However, even in the optimal scenarios with combination ICB, approximately half of patients fail to achieve long-lasting benefit20. This indicates the need for better predictive biomarkers of response and new rational targets for more effective combination treatments to overcome immune resistance. While elevated tumor PD-L1 expression and TMB have been found to correlate with clinical responses to ICB in melanoma21, these biomarkers cannot predict outcome in every situations accurately. As the longest & RC-3095 most consolidated scientific knowledge with ICB is within melanoma, these details can be today leveraged to attain a far more precise knowledge of the molecular determinants of activity of the therapies in sufferers. Here, we offer an updated summary of the immune system landscape of individual melanoma and exactly how it really is modulated by ICB, concentrating on research in patients. Furthermore, we showcase current restrictions of immunotherapy and delineate another potential avenues to boost the usage of these remedies. == Melanoma-specific T cells and their healing potential == Melanoma TILs are enriched for specificity to melanoma-associated antigens, indicating that anti-melanoma T cells can go through priming, extension, and recruitment towards the tumor (Fig. 1a). Endogeneous T cell replies to melanoma have already been exploited for multiple goals, including (1) id of the.